Given that both pembrolizumab + chemotherapy and nivolumab + ipilimumab are FDA-approved regimens for NSCLC patients with PD-L1 TPS ≥1%, these analyses are useful to inform physician decision-making and policy makers in this indication, when also considering other factors such as tolerability and cost of treatment. The gene discussed is CD274; the disease is non-small cell lung carcinoma.